Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

British Medical Journal

Volumn 324, Issue 7349, 2002, Pages 1287-1288

  Jüni, Peter ^a   Rutjes, Anne W S ^a   Dieppe, Paul A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTHRITIS; BLEEDING; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG INDUSTRY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PUBLICATION; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; STOMACH OBSTRUCTION; ULCER HEALING; ULCER PERFORATION;

EID: 0036606889     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.324.7349.1287     Document Type: Editorial

References (12)

1. Non-steroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
2. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety study
3. Missing data on Celebrex. Full study altered picture of drug
4. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib
5. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib
6. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. In reply
7. Researchers deny any attempt to mislead the public over JAMA article on arthritis drug
8. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis